LB-102 for Stable Schizophrenia Treatment
52-week Open Label Safety-Tolerability Study
- Age
- 18 – 65
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 900 (estimated)
- Sponsor
- LB Pharmaceuticals Inc. · Industry
This trial is looking for adults with stable schizophrenia who want to participate in a long-term treatment study. Participants will take LB-102 for 52 weeks to see how safe and tolerable the treatment is.
You may be able to join if
- I have been diagnosed with schizophrenia.
- I am clinically stable with a PANSS score of 80 or less.
- I have a CGI-S score of 3 or less.
- I am medically stable.
- I have a BMI between 18 and 40.
- I have been taking oral antipsychotic treatment for at least 30 days.
- I have a stable living environment.
You may not be able to join if
- I am sexually active and not willing to use highly effective contraception.
- I am breastfeeding.
- I have a history of treatment resistance to schizophrenia medications.
- I have a current diagnosis other than schizophrenia.
- I am at risk of suicidal behavior.
- I have a significant medical history involving my heart, lungs, liver, kidneys, blood, stomach, hormones, immune system, skin, nervous system, or cancer.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityPhase 3, open label, multicenter study designed to assess the long term safety and tolerability of LB-102 for the treatment of adult patients with stable schizophrenia
Loading trial locations…